UPCC 18122: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus In Patients With Estrogen Receptor-Positive, Her2-Negative, Locally Advanced
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6is and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting. We would like to rely on Advarra as the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 852800
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
